1/2 percutaneous intervention versus observational trial of arterial ductus in lower gestational age infants (PIVOTAL)
1/2 经皮介入治疗与低胎龄儿动脉导管观察性试验 (PIVOTAL)
基本信息
- 批准号:10349765
- 负责人:
- 金额:$ 81.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-21 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:AdoptionAgeArteriesBeliefBirthBlood CirculationBrainBrain InjuriesCaliberCardiopulmonaryCardiovascular systemCaregiversCaringCathetersCessation of lifeChronic lung diseaseClinicalComplexConsensusConsentDevicesDuct (organ) structureEffectivenessEquipoiseEthnic OriginExposure toFeasibility StudiesGestational AgeGoalsGrowth and Development functionHealth PersonnelHeartHumanInfantInfant HealthIntensive CareInternationalInterventionLeftLegal patentLinkLungMeasuresMechanical ventilationMediatingMedicalMedication ManagementMissionMorbidity - disease rateNeonatalNeonatal Intensive Care UnitsOperative Surgical ProceduresOutcomeOutputPatent Ductus ArteriosusPatient observationPatient-Focused OutcomesPatientsPeripheralPharmaceutical PreparationsPregnancyPremature InfantProceduresProcessPublic HealthPulmonary HypertensionPulmonary artery structureRaceRandomizedRandomized Controlled TrialsResortRespiratory DiseaseRiskSafetySeverity of illnessSiteTechniquesTestingThoracic cavity structureUncertaintyUnited States Food and Drug AdministrationUnited States National Institutes of HealthVeinsVentilatorVentricularVulnerable Populationsartery occlusionbaseefficacy studyexperiencefetalhemodynamicsimprovedin uterominimally invasivemortalityneonatal outcomeneurodevelopmentnovelpostnatalpreventrandomized trialrecruitrespiratorysecondary outcomesexspecific biomarkerstrial comparing
项目摘要
PROJECT SUMMARY/ABSTRACT
Patent ductus arteriosus (PDA), the most common cardiovascular condition in preterm infants, is associated with
mortality and harmful longer-term outcomes including chronic lung disease (CLD) and brain injury. Although
treatment does not benefit all infants with PDA, likely due to spontaneous closure, treatment of some infants with
symptomatic PDA is necessary. Medications are often used to close persistent preterm PDA in the initial four
weeks postnatal, but fail to close the PDA in 1/3 of infants, in whom an intervention is the only remaining definitive
closure option (failed pharmacological management). A treatment dilemma exists in the first postnatal month for
the subset of infants with persistent, hemodynamically significant, and clinically symptomatic PDA (HSPDA) after
postnatal week one following failed pharmacological management. Invasive, intrathoracic PDA surgery was tra-
ditionally employed for infants with HSPDA, but associations between surgery and adverse neurodevelopment
prompted widespread adoption of non-interventional, supportive treatment. This watchful-waiting approach
avoids or delays procedure-related complications, but prolongs developing brain and lung exposure to PDA-
related hemodynamics. Evidence is emerging that duration of HSPDA exposure is an important predictor of CLD
and/or death. Percutaneous catheter-based closure (PPC) is a novel, minimally-invasive means of closing a
HSPDA. A duct occluder (ADO-II AS) was recently approved (1/2019) by the US FDA for preterm infants weigh-
ing ≥700 grams. However, the effectiveness of PPC in improving important neonatal outcomes relative to sup-
portive (non-intervention) HSPDA management has never been evaluated via a randomized trial (RCT). The
uncertainty is whether PPC should be performed early (days 7-30 postnatal) for all infants with HSDPA to prevent
PDA-related complications or only rarely as a last resort following a prolonged trial of supportive management.
The objective in this application is to determine if PPC improves cardiopulmonary and neurodevelopmental out-
comes via a multicenter RCT comparing the two strategies. Aim 1 will determine the effect of PPC versus sup-
portive treatment on ventilator-free days (VFDs) at 30 days post-randomization (non-survivors will be scored as
having zero VFDs). Aim 2 will determine the effect of PPC versus supportive treatment on secondary cardiopul-
monary, safety and neurodevelopmental outcomes. Aim 3 will evaluate whether neurodevelopment at 3-4
months corrected age is mediated by improved neurodevelopmental profiles at 34-36 weeks postmenstrual age.
Aim 4 will evaluate potential effect modifiers of HDPSA (e.g., sex, race/ethnicity, gestational age, age at ran-
domization) on VFDs and secondary outcomes. This trial will immediately advance the care of extremely preterm
infants with HSPDA following failed medical management by identifying whether PPC or supportive treatment
better improves cardiopulmonary and neurodevelopmental outcomes.
项目概要/摘要
动脉导管未闭 (PDA) 是早产儿最常见的心血管疾病,与
死亡率和有害的长期结果,包括慢性肺病(CLD)和脑损伤。虽然
治疗并不能使所有患有 PDA 的婴儿受益,可能是由于自然闭合,对一些患有 PDA 的婴儿进行治疗
有症状的 PDA 是必要的。药物通常用于在最初的四个月内闭合持续性早产 PDA
产后几周,但 1/3 的婴儿未能闭合 PDA,其中干预是唯一有效的方法
关闭选项(药物治疗失败)。产后第一个月存在治疗困境
患有持续性、血流动力学显着且有临床症状的 PDA (HSPDA) 的婴儿亚群
药物治疗失败后的产后第一周。侵入性胸腔内 PDA 手术
通常用于患有 HSPDA 的婴儿,但手术与不良神经发育之间存在关联
促使人们广泛采用非介入性支持治疗。这种警惕等待的方式
避免或延迟手术相关并发症,但会延长发育中的大脑和肺部暴露于 PDA 的时间
相关血流动力学。越来越多的证据表明,HSPDA 暴露持续时间是慢性肺病 (CLD) 的重要预测因素
和/或死亡。经皮导管封堵术 (PPC) 是一种新颖的微创封堵方法
HSPDA。美国 FDA 最近批准 (1/2019) 导管封堵器 (ADO-II AS) 用于早产儿体重
≥700克。然而,PPC 在改善重要新生儿结局方面的有效性相对于支持
从未通过随机试验 (RCT) 评估过主动(非干预)HSPDA 管理。这
不确定的是是否应该对所有患有 HSDPA 的婴儿尽早(产后 7-30 天)进行 PPC 以预防
PDA 相关并发症或很少作为长期支持性治疗试验后的最后手段。
本申请的目的是确定 PPC 是否可以改善心肺和神经发育输出
通过比较这两种策略的多中心随机对照试验得出。目标 1 将确定 PPC 与 support 的效果
随机分组后 30 天无呼吸机日 (VFD) 的局部治疗(非幸存者将被评分为
具有零 VFD)。目标 2 将确定 PPC 与支持治疗对继发性心肺功能的影响
金钱、安全性和神经发育结果。目标 3 将评估 3-4 岁的神经发育是否
月校正年龄是通过经后 34-36 周神经发育状况的改善来调节的。
目标 4 将评估 HDPSA 的潜在影响因素(例如性别、种族/族裔、胎龄、随机年龄)
domization)对VFD和次要结果的影响。该试验将立即推进极早产儿的护理
通过确定是 PPC 还是支持治疗,治疗失败后患有 HSPDA 的婴儿
更好地改善心肺和神经发育结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carl Backes其他文献
Carl Backes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carl Backes', 18)}}的其他基金
1/2 CORD-CHD: Clamp OR Delay among neonates with Congenital Heart Disease
1/2 CORD-CHD:先天性心脏病新生儿的钳夹或延迟治疗
- 批准号:
10571076 - 财政年份:2023
- 资助金额:
$ 81.23万 - 项目类别:
Integrative Research Training Program in Pediatric Cardiopulmonary Disease
小儿心肺疾病综合研究培训计划
- 批准号:
10714157 - 财政年份:2023
- 资助金额:
$ 81.23万 - 项目类别:
1/2 percutaneous intervention versus observational trial of arterial ductus in lower gestational age infants (PIVOTAL)
1/2 经皮介入治疗与低胎龄儿动脉导管观察性试验 (PIVOTAL)
- 批准号:
10719307 - 财政年份:2022
- 资助金额:
$ 81.23万 - 项目类别:
Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
自发性动脉导管未闭 (PDA) 闭合及 PDA 相关结果的早期预测
- 批准号:
10311538 - 财政年份:2018
- 资助金额:
$ 81.23万 - 项目类别:
Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
自发性动脉导管未闭 (PDA) 闭合及 PDA 相关结果的早期预测
- 批准号:
10521258 - 财政年份:2018
- 资助金额:
$ 81.23万 - 项目类别:
Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
自发性动脉导管未闭 (PDA) 闭合及 PDA 相关结果的早期预测
- 批准号:
10063026 - 财政年份:2018
- 资助金额:
$ 81.23万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 81.23万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 81.23万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 81.23万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 81.23万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 81.23万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 81.23万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 81.23万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 81.23万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 81.23万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 81.23万 - 项目类别:
Directed Grant